These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 27411008)

  • 1. Unimolecular Polypharmacy for Treatment of Diabetes and Obesity.
    Tschöp MH; Finan B; Clemmensen C; Gelfanov V; Perez-Tilve D; Müller TD; DiMarchi RD
    Cell Metab; 2016 Jul; 24(1):51-62. PubMed ID: 27411008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut Peptide Agonism in the Treatment of Obesity and Diabetes.
    Grandl G; Novikoff A; DiMarchi R; Tschöp MH; Müller TD
    Compr Physiol; 2019 Dec; 10(1):99-124. PubMed ID: 31853954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists.
    Finan B; Clemmensen C; Müller TD
    Mol Cell Endocrinol; 2015 Dec; 418 Pt 1():42-54. PubMed ID: 26151488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases.
    Clemmensen C; Finan B; Müller TD; DiMarchi RD; Tschöp MH; Hofmann SM
    Nat Rev Endocrinol; 2019 Feb; 15(2):90-104. PubMed ID: 30446744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiagonist Unimolecular Peptides for Obesity and Type 2 Diabetes: Current Advances and Future Directions.
    Hasib A
    Clin Med Insights Endocrinol Diabetes; 2020; 13():1179551420905844. PubMed ID: 32110131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mono-ADP-ribosyltransferase as a potential pharmacological drug target in the GLP-1 based therapy of obesity and diabetes mellitus type 2.
    Bavec A
    Acta Chim Slov; 2013; 60(2):237-42. PubMed ID: 23878926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapy considerations in diabetes and obesity: setting patients up for success.
    Cornell S; D'Souza J
    Postgrad Med; 2014 Mar; 126(2):100-9. PubMed ID: 24685973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus.
    Baron AD; Kim D; Weyer C
    Curr Drug Targets Immune Endocr Metabol Disord; 2002 Apr; 2(1):63-82. PubMed ID: 12477297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy.
    Grundy SM
    Nat Rev Drug Discov; 2006 Apr; 5(4):295-309. PubMed ID: 16582875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The success of bariatric surgery as treatment of type 2 diabetes should be a call to revitalize anti-obesity drug discovery and development.
    Opgenorth TJ
    Curr Opin Investig Drugs; 2008 Apr; 9(4):355-6. PubMed ID: 18393101
    [No Abstract]   [Full Text] [Related]  

  • 12. Single-Molecule Combinatorial Therapeutics for Treating Obesity and Diabetes.
    Tschöp M; DiMarchi R
    Diabetes; 2017 Jul; 66(7):1766-1769. PubMed ID: 28603138
    [No Abstract]   [Full Text] [Related]  

  • 13. Synthetic agents in the context of metabolic/bariatric surgery: expanding the scope and impact of diabetes drug discovery.
    Janero DR
    Expert Opin Drug Discov; 2014 Mar; 9(3):221-8. PubMed ID: 24397872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes.
    Claus TH; Pan CQ; Buxton JM; Yang L; Reynolds JC; Barucci N; Burns M; Ortiz AA; Roczniak S; Livingston JN; Clairmont KB; Whelan JP
    J Endocrinol; 2007 Feb; 192(2):371-80. PubMed ID: 17283237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New and emerging pharmacologic therapies for type 2 diabetes, dyslipidemia, and obesity.
    Taylor JR; Dietrich E; Powell JG
    Clin Ther; 2013 Jan; 35(1):A3-17. PubMed ID: 23328274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus.
    Thondam SK; Cuthbertson DJ; Aditya BS; Macfarlane IA; Wilding JP; Daousi C
    Clin Endocrinol (Oxf); 2012 Oct; 77(4):635-7. PubMed ID: 22356092
    [No Abstract]   [Full Text] [Related]  

  • 17. Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity.
    Burcelin R; Gourdy P
    Obes Rev; 2017 Jan; 18(1):86-98. PubMed ID: 27636208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liraglutide for Type 2 diabetes and obesity: a 2015 update.
    Iepsen EW; Torekov SS; Holst JJ
    Expert Rev Cardiovasc Ther; 2015; 13(7):753-67. PubMed ID: 26106933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lignans' Potential in Pre and Post-onset Type 2 Diabetes Management.
    Barre DE; Mizier-Barre KA
    Curr Diabetes Rev; 2019; 16(1):2-11. PubMed ID: 30215336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GLP-1 as a target for therapeutic intervention.
    Rajeev SP; Wilding J
    Curr Opin Pharmacol; 2016 Dec; 31():44-49. PubMed ID: 27591964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.